This article was downloaded by:


On: 26 January 2011

Access details: Access Details: Free Access

Publisher Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-

41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information: http://www.informaworld.com/smpp/title~content=t713597286

Design of *Mycobacterium tuberculosis* Thymidine Monophosphate Kinase Inhibitors

H. Munier-Lehmann^{ab}; S. Pochet^c; L. Dugue^c; O. Dutruel^c; G. Labesse^d; D. Douget^d

^a Laboratoire de Chimie Structurale des Macromolécules, URA CNRS 2185, ^b Unité de Chimie

Structurale de Micromolecules, Institut Pasteur, Paris Cedex, France ^c Unité de Chimie Organique URA

CNRS 2128, Institut Pasteur, Paris Cedex, France ^d Centre de Biochimie Structurale, Université de

Montpellier I, Montpellier, France

Online publication date: 09 August 2003

To cite this Article Munier-Lehmann, H. , Pochet, S. , Dugue, L. , Dutruel, O. , Labesse, G. and Douget, D.(2003) 'Design of *Mycobacterium tuberculosis* Thymidine Monophosphate Kinase Inhibitors', Nucleosides, Nucleotides and Nucleic Acids, 22: 5, 801-804

To link to this Article: DOI: 10.1081/NCN-120022638 URL: http://dx.doi.org/10.1081/NCN-120022638

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: http://www.informaworld.com/terms-and-conditions-of-access.pdf

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

NUCLEOSIDES, NUCLEOTIDES & NUCLEIC ACIDS Vol. 22, Nos. 5–8, pp. 801–804, 2003

Design of *Mycobacterium tuberculosis* Thymidine Monophosphate Kinase Inhibitors

H. Munier-Lehmann,^{1,*} S. Pochet,² L. Dugue,² O. Dutruel,² G. Labesse,³ and D. Douget³

¹Laboratoire de Chimie Structurale des Macromolécules, URA CNRS 2185, and ²Unité de Chimie Organique URA CNRS 2128, Institut Pasteur, Paris Cedex, France ³Centre de Biochimie Structurale, Université de Montpellier I, Montpellier, France

M. tuberculosis is a major pathogen in the world and infects almost one third of the population. The current chemotherapy, which stands on a few molecules and involves long treatments of the patients, is challenged by emerging multiresistant strains. TMPK belongs to the family of nucleoside monophosphate kinase (NMPK): it catalyses the phophorylation of thymidine monophosphate (dTMP) to thymidine diphosphate (dTDP) utilizing ATP as its preferred phosphoryl donor. TMPK, essential for cell proliferation, was studied intensively the last years for its role in activation of antiviral drugs such AZT. Biochemical and physicochemical characterization of M. tuberculosis TMPK (TMPKmt) revealed distinct features when compared to its counterpart from yeast, human and E. coli, which renders this protein a good target for antituberculosis drugs.^[1] Based on the 3D-structure of TMPKmt (Fig. 1, [2]), different positions on the natural substrate (dTMP) were

801

DOI: 10.1081/NCN-120022638 Copyright © 2003 by Marcel Dekker, Inc.

www.dekker.com

1525-7770 (Print); 1532-2335 (Online)



^{*}Correspondence: H. Munier-Lehmann, Institut Pasteur, Unité de Chimie Structurale de Micromolecules, 28, rue de Dr. Roux, F-75724 Paris Cedex, France; E-mail: hmunier@pasteur.fr.

802 Munier-Lehmann et al.




Figure 1. Schematic drawing of the TMP-binding site of TMPKmt. [2]

chosen to introduce modifications with the aim of obtaining specific inhibitors of the target.

Modifications at the 5- (Table 1) and 5'-positions (Table 2) of dTMP were first explored. The values given in Tables 1 and 2 (μ M) correspond to the inhibitory constants of the different analogues and were determined using the coupled spectrophotometric assay at 334 nm. ^[3] The concentrations of ATP and dTMP were kept

Table 1. Modifications at the 5-position.

R	HO O N	R O NH	HO Q	R O H
СН₃	dΤ	27	AZT	28
н	dU	1020	AZdU	810
F	5FdU	212		
CI	5CIdU	10	5CIAZdU	16
Br	5BrdU	5	5BrAZdU	10,5
ı	5ldU	33		
он	5HOdU	270		
CF ₃	5CF ₃ dU	97		
сн₂он	5HOMedU	820		
CH₂CH₃	5EtdU	1140		
CH=CHBr (E)	BVDU	625		

Table 2. Modifications at the 5'-position.

constant at 0.5 mM and 0.05 mM, respectively, whereas the concentration of nucleoside analogues was varied within 0.01 and 2 mM. Non phosphorylated thymidine analogues are as potent inhibitors as their monophosphate counterparts:^[4] the 5′-phosphate group could be replaced by an amino or an azido function, or by a methyl group (Table 2). On the other hand, the 5-methyl group of dTMP could only be substituted by a bromine or a chlorine atom (Table 1).

ACKNOWLEDGMENTS

This work was supported by grants from the Institut Pasteur, the Institut National de la Santé et de la Recherche Médicale, the Centre National de la Recherche Scientifique (URA 2185 and 2128, and UMR 5048) and the Ministère de la Recherche (ACI "Molécules et Cibles Thérapeutiques").

REFERENCES

- 1. Munier-Lehmann, H.; Chaffotte, A.; Pochet, S.; Labesse, G. Protein Science **2001**, *10*, 1195–1205.
- Li de la Sierra, I.; Munier-Lehmann, H.; Gilles, A.-M.; Barzu, O.; Delarue, M. J. Mol. Biol. 2001, 311, 87–100.

804 Munier-Lehmann et al.

3. Blondin, C.; Serina, L.; Wiesmuller, L.; Gilles, A.-M.; Barzu, O. Anal. Biochem. **1994**, *220*, 219–221.

4. Pochet, S.; Dugué, L.; Douget, D.; Labesse, G.; Munier-Lehmann, H. Chem. Bio. Chem. **2002**, *I*, 108–110.